2,000 Amgen Inc. $AMGN Shares Sold by Gouws Capital LLC

Gouws Capital LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 32.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,100 shares of the medical research company’s stock after selling 2,000 shares during the period. Amgen makes up 0.8% of Gouws Capital LLC’s portfolio, making the stock its 21st biggest position. Gouws Capital LLC’s holdings in Amgen were worth $1,728,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. O Keefe Stevens Advisory Inc. grew its holdings in shares of Amgen by 1.0% in the third quarter. O Keefe Stevens Advisory Inc. now owns 52,256 shares of the medical research company’s stock worth $22,027,000 after acquiring an additional 504 shares during the period. Legacy Wealth Asset Management LLC boosted its position in Amgen by 79.4% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,657 shares of the medical research company’s stock worth $1,963,000 after purchasing an additional 2,061 shares during the last quarter. Market Street Wealth Management Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter valued at about $304,000. Monument Capital Management increased its position in shares of Amgen by 5.9% during the 3rd quarter. Monument Capital Management now owns 2,769 shares of the medical research company’s stock valued at $1,167,000 after purchasing an additional 155 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its position in shares of Amgen by 1.8% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 159,819 shares of the medical research company’s stock valued at $67,365,000 after purchasing an additional 2,800 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMGN. Bank of America raised their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Scotiabank raised their price objective on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Cantor Fitzgerald lifted their price objective on Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a research report on Monday. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Finally, TD Cowen increased their price target on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $389.71.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: An analyst upgrade helped drive buying interest in Amgen, with reports indicating the stock rose about 3% following the rating change. Amgen Stock Price Up 3% on Analyst Upgrade
• Positive Sentiment: Cantor Fitzgerald raised its price target for AMGN from $400 to $440, signaling greater confidence in Amgen’s earnings outlook and pipeline prospects. The target increase is a notable bullish catalyst, though it still leaves limited upside if shares remain near recent levels. Cantor Fitzgerald Raises Amgen Price Target
• Positive Sentiment: Amgen announced a head-to-head Phase 3 trial of its monthly diabetes treatment against semaglutide. Success could give the company a significant opportunity in the competitive GLP-1 market and provide a longer-term growth catalyst. Amgen Diabetes Drug Phase 3 Trial
• Positive Sentiment: The company also reported results from a Sjögren’s syndrome trial and participated in a $30 million Series A investment in AI-based genetic testing, potentially strengthening its research and precision-medicine capabilities. Amgen AI Genetic Testing Investment
• Neutral Sentiment: Morgan Stanley maintained a Hold rating, while its price target was reduced slightly from $362 to $359. This provides a counterpoint to Cantor Fitzgerald’s bullish view and suggests analyst opinion remains divided. Morgan Stanley Hold Rating on Amgen

Amgen Price Performance

NASDAQ AMGN traded up $8.41 during trading on Friday, hitting $415.85. 729,902 shares of the stock traded hands, compared to its average volume of 2,745,971. The company has a market capitalization of $224.82 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 2.98 and a beta of 0.41. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03. The firm has a 50-day simple moving average of $412.35 and a 200-day simple moving average of $371.88. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the company earned $6.02 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts predict that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.